Two major pharmaceutical companies - Eli Lilly and Novo Nordisk - have reached a groundbreaking agreement with the administration that will drastically reduce the prices of popular medications like Wegovy, Ozempic, and Zepbound. This pricing model could transform how obesity medications are covered, distributed, and accessed across Medicare, Medicaid, and direct-to-consumer platforms.
Tune in to learn what this new deal means for patients, healthcare providers, and public health overall—and why it’s being called a game changer for people struggling with obesity and related health conditions.
============================
FOLLOW ME 👇
Facebook: https://www.facebook.com/drshellymd
Instagram: https://www.instagram.com/drshellymd/
Twitter: https://twitter.com/drshellymd
LinkedIn: https://www.linkedin.com/in/drshellymd/
Website: https://drshellymd.com/
Podcast: https://drshellymd.com/podcast/
============================